Ovid Therapeutics (OVID) Enterprise Value (2017 - 2026)

Ovid Therapeutics (OVID) has reported Enterprise Value for 10 consecutive years, with $379.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Enterprise Value rose 2652.1% year-over-year to $379.8 million; the trailing twelve-month figure through Jun 2026 stood at $379.8 million (up 2652.1% YoY), and the FY2025 full-year result was $50.6 million, up 289.97% from the prior year.
• Enterprise Value rose to $379.8 million in Q2 2026 per OVID's latest filing, from $146.8 million in the prior quarter.
• Across five years, Enterprise Value topped out at $379.8 million in Q2 2026 and bottomed at -$22.3 million in Q2 2024.
• Historically, Enterprise Value has averaged $72.0 million across 5 years, with a median of $51.5 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Enterprise Value plunged 130.66% in 2022, then soared 14108.84% in 2023.
• Over 5 years, Enterprise Value stood at $2.1 million in 2022, then jumped by 5792.33% to $121.8 million in 2023, then plunged by 89.36% to $13.0 million in 2024, then surged by 289.97% to $50.6 million in 2025, then surged by 651.2% to $379.8 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered $379.8 million, $146.8 million, and $50.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.